Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients

Aktar, Gülay; Aslan Felek, Sevim; ugurlu, burak numan; Yerlikaya, Hüseyin Serdar

doi:10.24179/kbbbbc.2020-79556

Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients

Burak Numan UĞURLU, (Hitit Üniversitesi, Erol Olçok Eğitim ve Araştırma Hastanesi, Kulak Burun Boğaz Anabilim Dalı, Çorum, TÜRKİYE)

Hüseyin Serdar YERLİKAYA, (Hitit Üniversitesi, Erol Olçok Eğitim ve Araştırma Hastanesi, Kulak Burun Boğaz Anabilim Dalı, Çorum, TÜRKİYE)

Gülay AKTAR UĞURLU, (Hitit Üniversitesi, Erol Olçok Eğitim ve Araştırma Hastanesi, Kulak Burun Boğaz Anabilim Dalı, Çorum, TÜRKİYE)

Sevim FELEK (Hitit Üniversitesi, Erol Olçok Eğitim ve Araştırma Hastanesi, Kulak Burun Boğaz Anabilim Dalı, Çorum, TÜRKİYE)

Kulak Burun Boğaz ve Baş Boyun Cerrahisi

5 0

Yıl: 2021 Cilt: 29 Sayı: 2 Sayfa Aralığı: 95 - 99 Metin Dili: İngilizce DOI: 10.24179/kbbbbc.2020-79556 İndeks Tarihi: 14-10-2021

Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients

Öz:

Objective: There is no information about the relationship between coronavirus disease-2019 (COVID-19) and nasal mucociliary clearance (NMC). To investigate whether the severe acute respiratorysyndrome-CoV-2 has an effect on NMC. Material and Methods: Thirty-twopatients hospitalized in our hospital with the diagnosis of COVID-19 and confirmed by rt-PCR test were included in the study. Smokers and patients withchronic upper respiratory tract infection were excluded from the study. Thesaccharin test was performed to evaluate NMC. Patients over 50 and under 50years of age were examined in two groups as the reference values change withage. Patients with and without pulmonary symptoms were compared in termsof NMC. In addition, patients with and without cough were compared in termsof NMC in their age groups. Results: The study included a total of 32 patients, 18 (56%) males and 14 (44%) females, with a mean age of 50.8 years(range, 17-81 years). The mean clearance time of the patients over 50 yearsof age (n=15) was 14.20±4.80 min, while under 50 years of age (n=17) was11.94±3.61 min. When compared with the reference values in the literature,no significant difference was observed in both age groups (p>0.05). Therewas no significant difference in the patients over 50 years of age compared tothe patients with lung involvement (n=11, mean=14.64, SD=5.26) and without lung involvement (n=4, mean=13, SD=3.56) (p>0.05). There was no significant difference in the patients under 50 years of age compared to thepatients with lung involvement (n=7, mean=12.86, SD=4.78) and without lunginvolvement (n=10, mean=11.3, SD=2.63) (p>0.05). When the patients withand without cough complaint were compared between their age groups, nosignificant difference was observed (p>0.05). Conclusion: NMC has beenpreserved in COVID-19 patients. There is no significant difference in termsof lung involvement and cough complaints in NMC times.

Anahtar Kelime:

COVID-19 Hastalarında Nazal Mukosilier Klirensin Değerlendirilmesi

Öz:

Amaç: Koronavirüs hastalığı-2019’da [coronavirus disease-2019 (COVID-19)], nazal mukosilier klirensin (NMK) etkilenip etkilenmediği bilinmemektedir. Çalışmamızda, şiddetli akut solunum sendromu-CoV2’nin, NMK üzerinde bir etkisinin olup olmadığı araştırılmak istenmiştir. Gereç ve Yöntemler: Çalışmaya, hastanemize COVID-19 nedeni ile yatırılmış ve tanısı rt-PCR ile kesinleşmiş 32 hasta dâhil edildi. Sigara içen ve kronik üst solunum yolu enfeksiyonu olan hastalar hariç tutuldu. Tüm hastalara, NMK süresi ölçümü için sakkarin testi uygulandı. Referans değerlerinin farklılık gösterebilmesi nedeniyle 50 yaş altı ve 50 yaş üzeri hastalar 2 gruba ayrılarak incelendi. Her iki grupta da akciğer tutulumu olan ve olmayan hastalar, NMK süreleri açısından kıyaslandı. Ayrıca öksürük şikâyeti olan ve olmayan hastalar da kendi yaş gruplarında NMK açısından kıyaslandı. Bulgular: Çalışmaya, 18 (%56)’i erkek, 14 (%44)’ü kadın olmak üzere 32 hasta dâhil edildi. Ortalama yaş 50,8 idi (aralık 17-81). Elli yaş üstü hastaların (n=15) ortalama klirens süresi 14,20±4,80 dk iken, 50 yaşın altındaki hastaların (n=17) ortalama klirens süresi 11,94±3,61 dk idi. Literatürdeki referans değerler ile kıyaslandığında, her iki yaş grubunda da anlamlı farklılık izlenmedi (p>0,05). Elli yaş üzeri olup, akciğer tutulumu olan (n=11; ortalama=14,64; SS=5,26) ve akciğer tutulumu olmayan (n=4; ortalama=13; SS=3,56) hastalar kıyaslandığında, NMK süresinde anlamlı farklılık izlenmedi (p>0,05). Elli yaş altı hastalarda akciğer tutulumu olan (n=7; ortalama=12,86; SS=4,78) ve akciğer tutulumu olmayan (n=10; ortalama=11,3; SS=2,63) hastalarda NMK süresi arasında anlamlı farklılık izlenmedi (p>0,05). Öksürük şikâyeti olan ve olmayan hastalar, kendi yaş gruplarında kıyaslandığında anlamlı farklılık izlenmedi (p>0,05). Sonuç: NMK, COVID-19 hastalarında korunmuştur. NMK sürelerinde akciğer tutulumu ve öksürük şikâyeti açısından anlamlı farklılık yoktur.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-8.
2. Cingi C, Bayar Muluk N. All Around the Nose: Basic Science, Diseases and Surgical Management. 1st ed. Cham, Switzerland: Springer; 2020.
3. Xu L, Jiang Y. Mathematical modeling of mucociliary clearance: a mini-review. Cells. 2019;8(7):736.
4. Andersen I, Lundqvist GR, Proctor DF. Human nasal mucosal function in a controlled climate. Arch Environ Health. 1971;23(6):408-20.
5. Antunes MB, Cohen NA. Mucociliary clearance--a critical upper airway host defense mechanism and methods of assessment. Curr Opin Allergy Clin Immunol. 2007;7(1):5-10.
6. Uchida Y, Nohara K, Tanaka N, Fujii N, Fukatsu H, Kaneko N, et al. Comparison of saccharin time in nursing home residents with and without pneumonia: a preliminary study. In Vivo. 2020;34(2):845-8.
7. Deniz M, Gultekin E, Ciftci Z, Alp R, Ozdemir DN, Isik A, et al. Nasal mucociliary clearance in obstructive sleep apnea syndrome patients. Am J Rhinol Allergy. 2014;28(5):178-80.
8. Rosen EJ, Calhoun KH. Alterations of nasal mucociliary clearance in association with HIV infection and the effect of guaifenesin therapy. Laryngoscope. 2005;115(1):27-30.
9. Cinar F, Beder L. Nasal mucociliary clearance in coal mine workers. Otolaryngol Head Neck Surg. 2004;130(6):767-9.
10. Plaza Valía P, Carrión Valero F, Marín Pardo J, Bautista Rentero D, González Monte C. [Saccharin test for the study of mucociliary clearance: reference values for a Spanish population]. Arch Bronconeumol. 2008;44(10):540-5.
11. Ho JC, Chan KN, Hu WH, Lam WK, Zheng L, Tipoe GL, et al. The effect of aging on nasal mucociliary clearance, beat frequency, and ultrastructure of respiratory cilia. Am J Respir Crit Care Med. 2001;163(4):983-8.
12. Alho OP. Nasal airflow, mucociliary clearance, and sinus functioning during viral colds: effects of allergic rhinitis and susceptibility to recurrent sinusitis. Am J Rhinol. 2004;18(6):349-55.
13. Lovato A, de Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020;99(9):569-76.
14. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.
15. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-9.
16. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. Infectious Diseases (except HIV/AIDS); 2020 Feb. Available from:
17. Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope. 2020; 130(7):1787.
18. Sakakura Y, Ukai K, Majima Y, Murai S, Harada T, Miyoshi Y. Nasal mucociliary clearance under various conditions. Acta Otolaryngol. 1983;96(1-2):167-73. [PubMed]
19. Xie J, Hungerford D, Chen H, Abrams ST, Li S, Wang G, et al. Development and external validation of a prognostic multivariable model on admission for hospitalized patients with COVID-19. SSRN Electron J. 2020.
20. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002;109 (5):571-7.
21. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. Erratum in: Lancet. 2020;395(10229):1038. Erratum in: Lancet. 2020;395(10229):1038.
22. Bhowmik A, Chahal K, Austin G, Chakravorty I. Improving mucociliary clearance in chronic obstructive pulmonary disease. Respir Med. 2009;103(4):496-502.
23. Conrad C. Application of N-Acetylcysteine in pulmonary disorders. In: Frye RE, Berk M, eds. The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine. Singapore: Springer Singapore; 2019. p.255-76.
24. Zhang Q, Ju Y, Ma Y, Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: a randomized controlled trial. Medicine (Baltimore). 2018;97(45): e13087.
25. McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr. 2008;153(6):752-7.

APA	ugurlu b, Yerlikaya H, Aktar G, Aslan Felek S (2021). Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients. , 95 - 99. 10.24179/kbbbbc.2020-79556
Chicago	ugurlu burak numan,Yerlikaya Hüseyin Serdar,Aktar Gülay,Aslan Felek Sevim Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients. (2021): 95 - 99. 10.24179/kbbbbc.2020-79556
MLA	ugurlu burak numan,Yerlikaya Hüseyin Serdar,Aktar Gülay,Aslan Felek Sevim Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients. , 2021, ss.95 - 99. 10.24179/kbbbbc.2020-79556
AMA	ugurlu b,Yerlikaya H,Aktar G,Aslan Felek S Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients. . 2021; 95 - 99. 10.24179/kbbbbc.2020-79556
Vancouver	ugurlu b,Yerlikaya H,Aktar G,Aslan Felek S Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients. . 2021; 95 - 99. 10.24179/kbbbbc.2020-79556
IEEE	ugurlu b,Yerlikaya H,Aktar G,Aslan Felek S "Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients." , ss.95 - 99, 2021. 10.24179/kbbbbc.2020-79556
ISNAD	ugurlu, burak numan vd. "Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients". (2021), 95-99. https://doi.org/10.24179/kbbbbc.2020-79556

APA	ugurlu b, Yerlikaya H, Aktar G, Aslan Felek S (2021). Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients. Kulak Burun Boğaz ve Baş Boyun Cerrahisi, 29(2), 95 - 99. 10.24179/kbbbbc.2020-79556
Chicago	ugurlu burak numan,Yerlikaya Hüseyin Serdar,Aktar Gülay,Aslan Felek Sevim Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients. Kulak Burun Boğaz ve Baş Boyun Cerrahisi 29, no.2 (2021): 95 - 99. 10.24179/kbbbbc.2020-79556
MLA	ugurlu burak numan,Yerlikaya Hüseyin Serdar,Aktar Gülay,Aslan Felek Sevim Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients. Kulak Burun Boğaz ve Baş Boyun Cerrahisi, vol.29, no.2, 2021, ss.95 - 99. 10.24179/kbbbbc.2020-79556
AMA	ugurlu b,Yerlikaya H,Aktar G,Aslan Felek S Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients. Kulak Burun Boğaz ve Baş Boyun Cerrahisi. 2021; 29(2): 95 - 99. 10.24179/kbbbbc.2020-79556
Vancouver	ugurlu b,Yerlikaya H,Aktar G,Aslan Felek S Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients. Kulak Burun Boğaz ve Baş Boyun Cerrahisi. 2021; 29(2): 95 - 99. 10.24179/kbbbbc.2020-79556
IEEE	ugurlu b,Yerlikaya H,Aktar G,Aslan Felek S "Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients." Kulak Burun Boğaz ve Baş Boyun Cerrahisi, 29, ss.95 - 99, 2021. 10.24179/kbbbbc.2020-79556
ISNAD	ugurlu, burak numan vd. "Evaluation of Nasal Mucociliary Clearance in COVID-19 Patients". Kulak Burun Boğaz ve Baş Boyun Cerrahisi 29/2 (2021), 95-99. https://doi.org/10.24179/kbbbbc.2020-79556